<DOC>
	<DOC>NCT00369148</DOC>
	<brief_summary>Combination therapy of glinides with premixed insulin provides better glycemic control than premixed insulin alone.</brief_summary>
	<brief_title>Combination of Glinides With Premixed Insulin</brief_title>
	<detailed_description>Type 2 diabetic patients undergoing twice daily injections of premixed insulin are administered glinides (10mg of mitiglinide or 90 mg of nateglinide) at lunchtime without changing their insulin regimen. Twelve weeks after administration of the glinides, they are discontinued. HbA1c levels at the start of glinide administration, 12 weeks after administration, and 12 weeks after discontinuation are measured.</detailed_description>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Clinical diagnosis of type 2 diabetes Who undergoes twice daily injection of premixed insulin Whose HbA1c is more than 6.5% and less than 8.0% Whose change of HbA1c is more than 1.0% during 12 weeks observational period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>glinides</keyword>
	<keyword>premixed insulin</keyword>
	<keyword>combination therapy</keyword>
	<keyword>glycemic control</keyword>
</DOC>